Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)

Next Previous
Search
Trial Profile

A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI-882370 (Primary) ; Trametinib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms ENHANCE
  • Sponsors Xynomic Pharmaceuticals

Most Recent Events

  • 10 Apr 2025 Planned End Date changed from 1 Dec 2026 to 30 Dec 2028.
  • 10 Apr 2025 Planned primary completion date changed from 1 Dec 2025 to 30 Dec 2027.
  • 10 Apr 2025 Planned initiation date changed from 1 Dec 2024 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top